The miR-192-EGR1/HOXB9 Loop Regulates Glioma Cell Stemness and Malignant Phenotypes by Promoting Their Mesenchymal Transition
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.MicroRNA-192 (miR-192) suppresses glioma cell malignancy by downregulating EGR1 and HOXB9. Overexpressing miR-192 reduces proliferation, invasion, and stemness, inhibiting tumor growth.
Area Of Science
- Oncology
- Molecular Biology
- Gene Regulation
Background
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
- MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
- The specific role of miR-192 in glioma malignant phenotypes requires further elucidation.
Purpose Of The Study
- To investigate the regulatory effects of miR-192 on the malignant phenotypes of glioma cells.
- To identify the molecular mechanisms underlying miR-192's function in glioma.
- To explore the potential of miR-192 as a therapeutic target for glioma.
Main Methods
- Quantitative PCR, Western blotting, and immunofluorescence were used to detect regulatory factors.
- Lentiviral plasmid transfection was employed to construct glioma cell models.
- Cell proliferation, invasion, migration, and stemness were assessed using CCK-8, colony formation, Transwell, scratch, and CD133+ GSC assays.
- A subcutaneous xenograft mouse model was established to evaluate tumor growth in vivo.
Main Results
- MiR-192 expression was significantly reduced in glioma samples.
- MiR-192 directly downregulated EGR1 and HOXB9, forming a regulatory loop.
- Overexpression of miR-192 significantly decreased glioma cell proliferation, invasion, and migration.
- EGR1 or HOXB9 overexpression abrogated the inhibitory effects of miR-192.
- MiR-192 suppressed tumor growth, reduced stemness, and inhibited malignant phenotypes in vivo.
Conclusions
- MiR-192 acts as a tumor suppressor in glioma by targeting the EGR1/HOXB9 axis.
- MiR-192 reduces glioma stemness and malignant phenotypes through the EGR1-HOXB9 loop.
- MiR-192 holds potential as a therapeutic agent for inhibiting glioma progression.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...